Mairs & Power Inc Bristol Myers Squibb CO Transaction History

Mairs & Power Inc

$10.3 Billion
Q2 2024

A detailed history of Mairs & Power Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mairs & Power Inc holds 29,382 shares of BMY stock, worth $1.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

29,382

Previous 46,497 36.81%

Holding current value

$1.5 Million

Previous $2.52 Million 51.61%

% of portfolio

0.01%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $688,878 - $906,923	-17,115 Reduced 36.81%	29,382 $1.22 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $326,503 - $370,192	-6,805 Reduced 12.77%	46,497 $2.52 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $155,136 - $185,120	3,200 Added 6.39%	53,302 $2.73 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $676,213 - $756,111	-11,681 Reduced 18.91%	50,102 $2.91 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $1.03 Million - $1.15 Million	-16,242 Reduced 20.82%	61,783 $3.95 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $71,098 - $80,641	-1,082 Reduced 1.37%	78,025 $5.41 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $39,033 - $46,221	-570 Reduced 0.72%	79,107 $5.69 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $1,525 - $901,947	11,738 Added 17.28%	79,677 $5.66 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $60,419 - $66,543	-832 Reduced 1.21%	67,939 $5.23 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $102,548 - $122,964	-1,668 Reduced 2.37%	68,771 $5.02 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $357,497 - $416,758	-6,666 Reduced 8.65%	70,439 $4.39 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $327,210 - $383,284	-5,530 Reduced 6.69%	77,105 $4.56 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $911,129 - $992,220	-14,717 Reduced 15.12%	82,635 $5.52 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $387,015 - $435,278	-6,522 Reduced 6.28%	97,352 $6.15 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $232,461 - $263,421	-4,026 Reduced 3.73%	103,874 $6.44 Million
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $251,083 - $278,234	-4,372 Reduced 3.89%	107,900 $6.51 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $1.99 Million - $2.33 Million	-36,341 Reduced 24.45%	112,272 $6.6 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $3.43 Million - $4.98 Million	-73,844 Reduced 33.19%	148,613 $8.28 Million
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $330,937 - $431,677	-6,725 Reduced 2.93%	222,457 $14.3 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $357,129 - $423,428	-8,350 Reduced 3.52%	229,182 $11.6 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $527,586 - $583,396	-11,824 Reduced 4.74%	237,532 $10.8 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $270,720 - $322,800	-6,000 Reduced 2.35%	249,356 $11.9 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $57,293 - $74,295	-1,175 Reduced 0.46%	255,356 $13.3 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $1.24 Million - $1.4 Million	-22,413 Reduced 8.03%	256,531 $15.9 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $654,767 - $816,094	-12,958 Reduced 4.44%	278,944 $15.4 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $2.44 Million - $2.81 Million	-40,690 Reduced 12.23%	291,902 $18.5 Million
Q4 2017 Feb 14, 2018	SELL	$59.94 - $65.35 $434,744 - $473,983	-7,253 Reduced 2.13%	332,592 $20.4 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $18.8 Million - $21.7 Million	339,845	339,845 $21.7 Million

Others Institutions Holding BMY

# of Institutions

2,400

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $108B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mairs & Power Inc, based on Form 13F filings with the SEC.

News

Stay updated on Mairs & Power Inc with notifications on news.

Account